Biotie Therapies is a drug development biotechnology company with a focus on dependence disorders, inflammatory diseases and thrombosis.
The most advanced drugs in development are nalmefene for alcoholism (phase III) and impulse control disorders (phase II), monoclonal VAP-1 antibody and small molecule VAP-1 SSAO enzyme inhibitor for inflammatory diseases (late preclinical), and recombinant bioheparin for thrombosis (preclinical). The company is also developing a small molecule a2b1-integrin inhibitor for thrombosis and cancer, and has extensive immaterial property rights and know-how on its K5 polysaccharide technology platform to develop carbohydrate based pharmaceuticals.
BioTie's shares are quoted on the Helsinki Stock Exchange.
| Contact Details: |
| Tykistökatu 6 |
| Turku |
| |
| 20520 |
| Finland |
| Tel: | 02 - 274 89 00 |
| Fax: | 02 - 274 89 10 |
| Email: | info@biotie.com |
| WWW: | www.biotie.com/
|
| |
Recent Publications by Biotie Therapies: |  |
Targeting vascular adhesion protein-1 to treat autoimmune and inflammatory diseases.
The development of new, safe, and effective anti-inflammatory drugs... | 13th December, 2007
| Biotie Therapies Corp., Tykistokatu 6, Turku, FIN-20520, Finland.
| Ann N Y Acad Sci. 2007 Sep;1110:382-8.
DOI Direct Link |
Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.
BACKGROUND: Clinical studies with opioid antagonists for treatment of... | 25th July, 2007
| Biotie Therapies
| Alcohol Clin Exp Res. 2007 Jul;31(7):1179-87. Epub 2007 Apr 19.
DOI Direct Link |
Safety of blocking vascular adhesion protein-1 in patients with contact dermatitis.
Vascular adhesion protein-1 mediates leukocyte binding to vascular... | 17th September, 2005
| Biotie Therapies Corp.,
| Basic Clin Pharmacol Toxicol. 2005 Jun;96(6):429-35.
DOI Direct Link |
Altered expression of syndecan-1 in prostate cancer.
Syndecan-1 is a cell surface heparan sulfate proteoglycan expressed by... | 21st April, 2004
| BioTie Therapies Corp., Turku, Finland.
| APMIS. 2004 Feb;112(2):89-97.
DOI Direct Link |
[From magic bullets to real drugs--immunotherapy available on the pharmacy's shelves]
Syndecan-1 is a cell surface heparan sulfate proteoglycan expressed by... | 24th July, 2003
| Biotie Therapies Oyj
| Duodecim. 2003;119(8):793-800.
|
→View more Biotie Therapies research publications. |
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 447 times since April 2007, the link to the organisation's website has been followed 59 times
Recent Search Terms used to find this page: preclinical biotie 2009 | BioTie Therapies company profile | Biotie Therapies Oyj Tykistokatu 6 | BIOTIE THERAPIES OYJ | BioTie Therapies | k5 polysaccharide research companies | k5 polysaccharide research companies | Biotie Therapies corp.fi | biotie therapies contact details | biotie therapies contact details | .
Search for more companies in Turku
Search for more companies in
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
Biotie Therapies
